Neximmune Price Prediction

NEXIDelisted Stock  USD 2.43  0.22  9.95%   
As of 30th of November 2024, the relative strength index (RSI) of Neximmune's share price is approaching 31. This indicates that the pink sheet is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Neximmune, making its price go up or down.

Oversold Vs Overbought

31

 
Oversold
 
Overbought
The successful prediction of Neximmune's future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Neximmune, which may create opportunities for some arbitrage if properly timed.
Using Neximmune hype-based prediction, you can estimate the value of Neximmune from the perspective of Neximmune response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Neximmune to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Neximmune because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Neximmune after-hype prediction price

    
  USD 2.43  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neximmune's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
2.352.352.67
Details
Naive
Forecast
LowNextHigh
2.542.542.54
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.642.834.02
Details

Neximmune After-Hype Price Prediction Density Analysis

As far as predicting the price of Neximmune at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Neximmune or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Neximmune, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Neximmune Estimiated After-Hype Price Volatility

In the context of predicting Neximmune's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Neximmune's historical news coverage. Neximmune's after-hype downside and upside margins for the prediction period are 2.43 and 2.43, respectively. We have considered Neximmune's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
2.43
2.43
After-hype Price
2.43
Upside
Neximmune is very steady at this time. Analysis and calculation of next after-hype price of Neximmune is based on 3 months time horizon.

Neximmune Pink Sheet Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Neximmune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neximmune backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Neximmune, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
 0.00  
0.00
 0.00  
 0.00  
0 Events / Month
14 Events / Month
Uncertain
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
2.43
2.43
0.00 
0.00  
Notes

Neximmune Hype Timeline

Neximmune is now traded for 2.43. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Neximmune is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is now at 0.0%. %. The volatility of related hype on Neximmune is about 0.0%, with the expected price after the next announcement by competition of 2.43. About 17.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.38. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Neximmune recorded a loss per share of 24.11. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 19th of October 2023. Given the investment horizon of 90 days the next anticipated press release will be uncertain.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Neximmune Related Hype Analysis

Having access to credible news sources related to Neximmune's direct competition is more important than ever and may enhance your ability to predict Neximmune's future price movements. Getting to know how Neximmune's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Neximmune may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
ZVSAZyVersa Therapeutics(0.1)4 per month 0.00 (0.15) 7.57 (9.60) 78.93 
PALIPalisade Bio 0.03 7 per month 0.00 (0.12) 5.97 (8.55) 24.25 
UNCYUnicycive Therapeutics(0.05)7 per month 4.13  0.20  10.26 (7.32) 29.22 
APGNApexigen(0.02)5 per month 5.50 (0) 7.89 (11.11) 58.79 
IMMXImmix Biopharma(0.04)4 per month 4.54 (0.01) 9.38 (8.22) 32.68 
RNAZTranscode Therapeutics(0.02)5 per month 6.97  0.06  22.00 (11.43) 68.80 
LABPLandos Biopharma(0.20)1 per month 3.81  0.09  8.58 (7.05) 19.47 
ONCROncorus 0.01 3 per month 0.00 (0.16) 10.00 (21.20) 120.67 
XBIOXenetic Biosciences(0.24)7 per month 4.24  0.04  7.65 (7.09) 26.99 
EFTREffector Therapeutics(0.06)4 per month 0.00 (0.31) 8.70 (27.78) 88.91 
VIRIVirios Therapeutics Llc 0.14 5 per month 0.00 (0.06) 12.46 (10.62) 50.54 
ZURAZura Bio Limited(0.21)9 per month 0.00 (0.10) 7.95 (7.94) 26.70 
NAVBNavidea Biopharmaceuticals 0.00 0 per month 0.00 (0.15) 12.50 (12.50) 40.40 
CNSPCns Pharmaceuticals(0.01)6 per month 0.00 (0.06) 9.09 (8.33) 39.29 
SONNSonnet Biotherapeutics Holdings 1.15 6 per month 0.00 (0.17) 12.31 (9.79) 37.58 
MREOMereo BioPharma Group(0.15)9 per month 0.00 (0.13) 4.80 (6.31) 17.36 
TERNTerns Pharmaceuticals 0.03 11 per month 0.00 (0.07) 6.02 (5.96) 34.09 
PDSBPDS Biotechnology Corp 0.14 10 per month 0.00 (0.11) 7.67 (6.76) 31.83 
INZYInozyme Pharma(0.17)9 per month 0.00 (0.31) 5.07 (7.92) 16.62 
HOOKHookipa Pharma(0.19)7 per month 0.00 (0.30) 6.85 (6.67) 22.98 

Neximmune Additional Predictive Modules

Most predictive techniques to examine Neximmune price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Neximmune using various technical indicators. When you analyze Neximmune charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Neximmune Predictive Indicators

The successful prediction of Neximmune stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Neximmune, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Neximmune based on analysis of Neximmune hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Neximmune's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Neximmune's related companies.

Story Coverage note for Neximmune

The number of cover stories for Neximmune depends on current market conditions and Neximmune's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Neximmune is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Neximmune's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Neximmune Short Properties

Neximmune's future price predictability will typically decrease when Neximmune's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Neximmune often depends not only on the future outlook of the potential Neximmune's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neximmune's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares OutstandingM
Cash And Short Term Investments4.6 M
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Consideration for investing in Neximmune Pink Sheet

If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.